Human Cytomegalovirus: Pathogenesis, Prevention, and Treatment

Overview

Journal Mol Biomed

Specialties Biomedical Engineering
General Medicine
Pathology

Date 2024 Nov 25

PMID 39585514

Authors

Zifang Shang

Xin Li

Affiliations

Soon will be listed here.

Abstract

Human cytomegalovirus (HCMV) infection remains a significant global health challenge, particularly for immunocompromised individuals and newborns. This comprehensive review synthesizes current knowledge on HCMV pathogenesis, prevention, and treatment strategies. We examine the molecular mechanisms of HCMV entry, focusing on the structure and function of key envelope glycoproteins (gB, gH/gL/gO, gH/gL/pUL128-131) and their interactions with cellular receptors such as PDGFRα, NRP2, and THBD. The review explores HCMV's sophisticated immune evasion strategies, including interference with pattern recognition receptor signaling, modulation of antigen presentation, and regulation of NK and T cell responses. We highlight recent advancements in developing neutralizing antibodies, various vaccine strategies (live-attenuated, subunit, vector-based, DNA, and mRNA), antiviral compounds (both virus-targeted and host-targeted), and emerging cellular therapies such as TCR-T cell approaches. By integrating insights from structural biology, immunology, and clinical research, we identify critical knowledge gaps and propose future research directions. This analysis aims to stimulate cross-disciplinary collaborations and accelerate the development of more effective prevention and treatment strategies for HCMV infections, addressing a significant unmet medical need.

References

Muller C, Alain S, Baumert T, Ligat G, Hantz S . Structures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses. Life (Basel). 2021; 11(2). PMC: 7920273. DOI: 10.3390/life11020150. View

Li Q, Fischer E, Cohen J . Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-Like Process. J Virol. 2016; 90(21):9766-9781. PMC: 5068528. DOI: 10.1128/JVI.01092-16. View

Dassa L, Seidel E, Oiknine-Djian E, Yamin R, Wolf D, Le-Trilling V . The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack. J Virol. 2018; 92(17). PMC: 6096798. DOI: 10.1128/JVI.00162-18. View

Kim H, Lee Y, Lee S, Park B . HCMV-encoded viral protein US12 promotes autophagy by inducing autophagy flux. Biochem Biophys Res Commun. 2023; 654:94-101. DOI: 10.1016/j.bbrc.2023.03.004. View

Wild J, Staton C, Chapple K, Corfe B . Neuropilins: expression and roles in the epithelium. Int J Exp Pathol. 2012; 93(2):81-103. PMC: 3385701. DOI: 10.1111/j.1365-2613.2012.00810.x. View

Goldmacher V, Bartle L, Skaletskaya A, Dionne C, Kedersha N, Vater C . A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci U S A. 1999; 96(22):12536-41. PMC: 22976. DOI: 10.1073/pnas.96.22.12536. View

Si Z, Zhang J, Shivakoti S, Atanasov I, Tao C, Hui W . Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate. PLoS Pathog. 2018; 14(12):e1007452. PMC: 6307773. DOI: 10.1371/journal.ppat.1007452. View

Landais I, Pelton C, Streblow D, DeFilippis V, McWeeney S, Nelson J . Human Cytomegalovirus miR-UL112-3p Targets TLR2 and Modulates the TLR2/IRAK1/NFκB Signaling Pathway. PLoS Pathog. 2015; 11(5):e1004881. PMC: 4425655. DOI: 10.1371/journal.ppat.1004881. View

Won T, Wood M, Hughes D, Talor M, Ma Z, Schneider J . Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs. EBioMedicine. 2022; 75:103812. PMC: 8756077. DOI: 10.1016/j.ebiom.2022.103812. View

10.

Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim D . Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation. 2019; 103(9):1953-1963. DOI: 10.1097/TP.0000000000002626. View

11.

Mercorelli B, Sinigalia E, Loregian A, Palu G . Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev Med Virol. 2007; 18(3):177-210. DOI: 10.1002/rmv.558. View

12.

Isomura H, Stinski M . Coordination of late gene transcription of human cytomegalovirus with viral DNA synthesis: recombinant viruses as potential therapeutic vaccine candidates. Expert Opin Ther Targets. 2012; 17(2):157-66. DOI: 10.1517/14728222.2013.740460. View

13.

Ma C, Chen P, Du J, Wang L, Lu N, Sun J . Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation. J Immunother Cancer. 2024; 12(1). PMC: 10773422. DOI: 10.1136/jitc-2023-007735. View

14.

Abate D, Watanabe S, Mocarski E . Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol. 2004; 78(20):10995-1006. PMC: 521853. DOI: 10.1128/JVI.78.20.10995-11006.2004. View

15.

Chang W, Barry P, Szubin R, Wang D, Baumgarth N . Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology. 2009; 390(2):330-7. PMC: 2747589. DOI: 10.1016/j.virol.2009.05.013. View

16.

Mouna L, Hernandez E, Bonte D, Brost R, Amazit L, Delgui L . Analysis of the role of autophagy inhibition by two complementary human cytomegalovirus BECN1/Beclin 1-binding proteins. Autophagy. 2015; 12(2):327-42. PMC: 4836022. DOI: 10.1080/15548627.2015.1125071. View

17.

Painter W, Robertson A, Trost L, Godkin S, Lampert B, Painter G . First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012; 56(5):2726-34. PMC: 3346600. DOI: 10.1128/AAC.05983-11. View

18.

Hegde N, Tomazin R, Wisner T, Dunn C, Boname J, Lewinsohn D . Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002; 76(21):10929-41. PMC: 136637. DOI: 10.1128/jvi.76.21.10929-10941.2002. View

19.

Fu Y, Guo Y, Zou H, Su S, Wang S, Yang Q . Human cytomegalovirus protein UL42 antagonizes cGAS/MITA-mediated innate antiviral response. PLoS Pathog. 2019; 15(5):e1007691. PMC: 6527189. DOI: 10.1371/journal.ppat.1007691. View

20.

Costa B, Becker J, Krammer T, Mulenge F, Duran V, Pavlou A . Human cytomegalovirus exploits STING signaling and counteracts IFN/ISG induction to facilitate infection of dendritic cells. Nat Commun. 2024; 15(1):1745. PMC: 10897438. DOI: 10.1038/s41467-024-45614-3. View